On January 14, Andon Health Co.Ltd(002432) issued a supplementary announcement on the signing of major contracts for daily operation by the company’s U.S. subsidiaries, saying that the company disclosed the announcement on the signing of major contracts for daily operation by the company’s U.S. subsidiaries in the morning of January 14, 2022. It should be noted that the U.S. government has the right to terminate the contract at any time due to its own factors. Please make careful decisions and pay attention to preventing investment risks.
According to the announcement, the U.S. government can request to stop the execution of the contract and cancel the subsequent procurement without any reason. The Seller shall bear the corresponding risks and possible losses.
This morning, Andon Health Co.Ltd(002432) announced that the U.S. subsidiary signed a purchase contract of 8.102 billion yuan for covid-19 household kit. Earlier, on January 12, Andon Health Co.Ltd(002432) announced an order of about 416 million yuan from its U.S. subsidiary.
Affected by this, Andon Health Co.Ltd(002432) opened again today, closing at 75.28 yuan, a record high, with a total market value of 36.03 billion yuan. This is Andon Health Co.Ltd(002432) the fourth consecutive trading day limit and the 27th limit in nearly two months.
In addition, Andon Health Co.Ltd(002432) also gives special tips on quality risk and supply risk.
The company said that in the case of mass production, individual product batches may have quality problems, lead to return or even recall. This risk may lead to the buyer’s return, termination of the contract and cancellation of subsequent procurement, and the seller will bear relevant losses.
If the epidemic situation in China changes or the company’s production capacity and output decline due to other force majeure factors, resulting in failure to produce and deliver on time, the company may breach the contract, or the buyer may terminate the contract and cancel subsequent contract procurement. The company shall also bear relevant losses if the contract cannot be fully implemented.
On the same day, the company replied to the letter of concern from the Shenzhen Stock Exchange. At present, the company has obtained the authorization of the U.S. FDA EUA and can be sold in the United States, but it has not obtained the Chinese license and cannot be put into use in China. The above contents of the company’s announcement specifically emphasize the possible reduction of antigen detection sensitivity. In the future, the company will strengthen the control over the integrity of the wording of the announcement, but the company has no behavior and motivation to hype the stock price through information disclosure.
